[Value of autocrine motility factors in the prediction of the disease progression of PBC- associated hepatocellular carcinoma].

To clarify the value of autocrine motility factor (ATX) in predicting the disease progression of primary biliary cholangitis (PBC)-associated hepatocellular carcinoma (HCC). A prospective cohort of 179 newly diagnosed autoimmune liver disease (PBC) patients admitted to the Department of Hepatology at the Fifth Medical Center of the People's Liberation Army General Hospital from January 2016 to January 2018 was selected. All PBC patients received ursodeoxycholic acid (UDCA) treatment and were followed up.The endpoint of the follow-up was the occurrence of primary liver cancer. The relationship between ATX and the clinical characteristics of patients and its significance in predicting disease progression and HCC were analyzed. The peripheral blood ATX level was significantly higher in PBC patients than that of alcoholic cirrhosis ( = 3.278, = 0.001) and healthy controls ( = 6.594, < 0.001), but there was no significant difference in ATX levels compared with patients with non-PBC- associated HCC ( = -0.240, = 0.811). The expression of ATX in liver tissue of PBC patients was significantly higher than that of healthy individuals ( = -3.633, < 0.001) and patients with alcoholic cirrhosis ( = -3.283, < 0.001), while the expression of ATX in the advanced stage was significantly higher than that in early-stage PBC patients ( = -2.018, = 0.034). There was a significant difference in baseline ATX levels between PBC patients without HCC and PBC patients with HCC (228.451 ± 124.093 ng/ml vs. 301.583 ± 100.512 ng/ml, = 2.339, = 0.021). Multivariate logistic regression analysis showed that ATX was an independent predictor of PBC progression to HCC ( = 1.245, 95% 1.097-1.413). The baseline peripheral blood ATX level in predicting AUROC of PBC-associated HCC was 0.714, 95% 0.597-0.857 and the sensitivity and specificity were 84.6%, and 59.0%, respectively. The optimal cutoff value for predicting serum ATX levels in the occurrence of HCC was 235.254 ng/ml. Patients with PBC have significantly higher levels of ATX expression in their peripheral blood and liver tissue, which can be utilized to assess treatment effectiveness and predict disease progression.